Evidence map›Paper›PMID 40765082›Full record

ReviewCurrent medicinal chemistry2026

Participation of MDM2 in Pro-Apoptotic and Androgen Receptor- Degrading Potency of Selected Steroid and Terpenoid Derivatives.

Alexander Y Misharin, Alexander V Veselovsky, Vladimir A Zolottsev

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alexander Y MisharinV.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119435, Moscow, Russia.
Alexander V VeselovskyV.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119435, Moscow, Russia.
Vladimir A ZolottsevV.N. Orekhovich Institute of Biomedical Chemistry, 10, Pogodinskaya Street, 119435, Moscow, Russia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review aims to highlight anti-proliferative, pro-apoptotic, and androgen receptor-degrading activity of selected steroid and terpenoid derivatives in cancer cells, primarily in prostate cancer cells. Steroid and terpenoid derivatives (steroid hybrids, comprising androstane or pregnane skeleton associated with nitrogen containing heterocycle, some natural sterols, bile acids, and related semi-synthetic derivatives; oleanane and ursane type pentacyclic triterpenoids; lanostane and dammarane type tetracyclic triterpenoids), were reported earlier to cause the death of cancer cells via apoptosis; some compounds exhibited significant anticancer potency in vivo and may be considered as promising anticancer agents. The presented data indicate that direct interaction of steroid and terpenoid derivatives with the key oncogenic protein MDM2 makes a significant contribution to anti-proliferative, pro-apoptotic, and androgen receptordegrading activity of these compounds. It triggers apoptosis, which leads to cell death. Structural optimization of steroid and terpenoid derivatives can significantly increase their affinity to MDM2 and improve their anti-proliferative, pro-apoptotic, and androgen receptor-degrading activity.

Indexed as

Antineoplastic AgentsApoptosisProto-Oncogene Proteins c-mdm2Receptors, AndrogenSteroidsTerpenesAnimalsCell ProliferationHumansMaleProstatic NeoplasmsAntineoplastic AgentsMDM2 protein, humanProto-Oncogene Proteins c-mdm2Receptors, AndrogenSteroidsTerpenesandrogen receptor degradationapoptosisMDM2prostate cancer cellsSteroid derivativesterpenoid derivatives

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.